Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Kindred Biosciences (KIN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 403,190
  • Shares Outstanding, K 33,910
  • Annual Sales, $ 0 K
  • Annual Income, $ -30,880 K
  • 36-Month Beta 0.23
  • Price/Sales 629.98
  • Price/Cash Flow N/A
  • Price/Book 3.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.42
  • Number of Estimates 2
  • High Estimate -0.40
  • Low Estimate -0.43
  • Prior Year -0.35
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.55 +0.35%
on 12/17/18
13.96 -16.98%
on 11/29/18
-1.29 (-10.02%)
since 11/16/18
3-Month
11.46 +1.13%
on 10/12/18
15.11 -23.30%
on 10/31/18
-1.76 (-13.18%)
since 09/17/18
52-Week
7.55 +53.51%
on 02/06/18
15.75 -26.41%
on 08/13/18
+3.44 (+42.21%)
since 12/15/17

Most Recent Stories

More News
Recent Analysis Shows Spirit Airlines, Cactus, Evergy, ADDvantage Technologies Group, Kindred Biosciences, and Farfetch Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Spirit Airlines, Inc. (NYSE:SAVE),...

KIN : 11.49 (-3.36%)
WHD : 28.22 (+1.55%)
FTCH : 21.40 (-10.39%)
AEY : 1.36 (+5.43%)
EVRG : 59.15 (-2.30%)
SAVE : 58.65 (-0.61%)
Kindred Bio: 3Q Earnings Snapshot

BURLINGAME, Calif. (AP) _ Kindred Biosciences Inc. (KIN) on Wednesday reported a loss of $13 million in its third quarter.

KIN : 11.49 (-3.36%)
Kindred Biosciences Announces Third Quarter 2018 Financial Results

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the third quarter ended September...

KIN : 11.49 (-3.36%)
Positive Developments for Treating Patients With Recurrent Malignant Tumors Significant for Novel Therapeutic Strategies

Financialnewsmedia.com News Commentary

KIN : 11.49 (-3.36%)
ARRY : 15.93 (-0.25%)
SBBP : 4.31 (-1.37%)
PFE : 43.15 (-1.48%)
MBRX : 1.16 (-7.94%)
Kindred Biosciences Announces Positive Results from Pilot Effectiveness Study of its Fully Caninized IL-31 Antibody for the Treatment of Atopic Dermatitis in Dogs and Issuance of U.S. Patent

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced positive topline results from its pilot effectiveness...

KIN : 11.49 (-3.36%)
Kindred Biosciences to Announce Third Quarter 2018 Financial Results

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its third quarter 2018 financial...

KIN : 11.49 (-3.36%)
Kindred Biosciences Elects Denise Bevers to its Board of Directors and Promotes Her to President

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that Denise Bevers, Co-Founder and Chief Operating...

KIN : 11.49 (-3.36%)
Kindred Biosciences to Present at Cantor Global Healthcare Conference and Ladenburg Thalmann 2018 Healthcare Conference

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the Cantor Global Healthcare Conference on October...

KIN : 11.49 (-3.36%)
Kindred Bio: 1Q Earnings Snapshot

BURLINGAME, Calif. (AP) _ Kindred Biosciences Inc. (KIN) on Tuesday reported a loss of $10 million in its first quarter.

KIN : 11.49 (-3.36%)
Kindred Biosciences Announces First Quarter 2018 Financial Results

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March...

KIN : 11.49 (-3.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade KIN with:

Business Summary

Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have...

See More

Key Turning Points

2nd Resistance Point 12.47
1st Resistance Point 12.18
Last Price 11.49
1st Support Level 11.75
2nd Support Level 11.60

See More

52-Week High 15.75
Fibonacci 61.8% 12.62
Fibonacci 50% 11.65
Last Price 11.49
Fibonacci 38.2% 10.68
52-Week Low 7.55

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar